Introduction
Interferon regulatory factor (IRF) genes encode a family of DNA-binding proteins, the IRF family, which plays an essential role in gene regulation in response to interferon and viral infections (Maniatis et al., 1992; Vilcek and Sen, 1994; Nguyen et al., 1997a) . Proteins of the IRF family have been shown to be involved in the regulation of the pleiotropic activities elicited by IFNs including the modulation of the immune response, in¯ammation, hematopoiesis, cell proliferation and dierentiation (De Maeyer and De Maeyer, 1988; Taniguchi et al., 1995) . This family includes IRF-1, IRF-2, ICSBP, ISGF3g, the recently described ICSAT/Pip/LSIRF, IRF3 and v-IRF encoded by a non structural gene of the human herpes virus 8 (HHV-8) (Nguyen et al., 1997b) .
IRF-1 and IRF-2 were originally identi®ed as transcription factors able to bind with dierent anity and activity to the same sequence (named ISRE/IRF-E) in the promoters of type I IFN and other cytokine-inducible genes (Harada et al., 1989; Miyamoto et al., 1988; Fujita et al., 1989; Pine, 1992; Hiscott et al., 1995) . IRF-1 and IRF-2 exhibit 62% homology in the N-terminal region which confers DNA binding speci®city but are functionally distinct factors; IRF-1 acts as a transcriptional activator, whereas IRF-2 functions as a repressor of IRF-1-activated gene expression (Miyamoto et al., 1988; Harada et al., 1989 Harada et al., , 1990 .
IRF-1 and IRF-2 are also key transcription factors in the regulation of growth, cell cycle and apoptosis and function as an anti-oncogene and oncogene, respectively (Harada et al., , 1994a Tamura et al., 1995) . The ratio of IRF-1: IRF-2 expression oscillates during the cell cycle, being at its highest in growth-arrested cells and at its lowest following growth stimulation (Watanabe et al., 1991; Harada et al., 1993) ; alterations in IRF-1 : IRF-2 expression levels can have signi®cant consequences for cell growth. Ectopic overexpression of IRF-1 results in strong inhibition of cell growth, and deletions of the IRF-1 gene have been demonstrated in a number of human leukemias and myelodysplasias Willman et al., 1993) . These observations suggest a potential link between the transcriptional properties (DNA binding and transactivation/repression) and their respective antioncogenic and oncogenic potentials.
It is postulated that the tumor suppressor activity of IRF-1 aects cell growth by acting through the activation of a set of genes whose products are required for the negative regulation of cell growth . A number of IFN-stimulated genes (ISGs) have been shown to be involved in regulating cell proliferation and are target genes of IRFs (Lengyel, 1993; Reis et al., 1994) . The two best characterized ISGs, the 2-5A synthetase and the double-stranded RNA-dependent protein kinase (PKR), participate in regulation of cell growth and are targets of IRF-1 regulation (Coccia et al., , 1995 Reis et al., 1994; Tanaka and Samuel, 1994; Kirchho et al., 1995; Rysiecki et al., 1989) . In particular the 2-5A synthetase, when activated by double-stranded RNA (dsRNA), converts ATP into 2'-5' linked oligomers of adenosine (Williams and Silvermann, 1985; Hovanessian, 1991) which in turn activates a latent endonuclease responsible for degradation of viral and cellular RNAs (Clemens and Williams, 1978; Wreschner et al., 1981) . In addition to a role in mediating resistance to virus infection, the 2-5A system is also implicated in the control of cell growth and proliferation (Williams and Silvermann, 1985) . Overexpression of the wild-type 2-5A synthetase gene inhibits cell proliferation (Rysiecki et al., 1989) , while overexpression of catalytically inactive mutants of RNase L renders cells resistant to the antiviral and antiproliferative eects of IFNs (Hassel et al., 1993) .
More recently Tanaka et al. (1996) showed that the, p21 (WAF1/CP1) gene, a member of the family of cyclin-dependent kinase (CDK) inhibitors which plays a primary role in cell cycle regulation (Sherr and Roberts, 1995; Ozawa et al., 1996) , is regulated in response to DNA damage by both IRF-1 and another tumor suppressor, p53. The induction of p21 is essential for DNA damage-induced cell-cycle arrest and dependent on p53 (El-Deiry et al., 1994 . In addition, a p53-independent activation of p21 has also been described in response to either growth factor stimuli or exposure to dierentiation-inducing agents (Steinman et al., 1994; Jiang et al., 1994; Zhang et al., 1995; Zeng and El-Deiry, 1996) suggesting also a role of p21 in growth arrest associated with terminal dierentiation (Hirama and Koeer, 1995; Halevy et al., 1995; Macleod et al., 1995; Parker et al., 1995) . The p53-independent induction of p21 in response to EGF and IFN-g is mediated by the signal transducer and activator of transcription STAT1, thus establishing a link between the IFN signaling pathway and the control of cell cycle (Chin et al., 1996) . In addition to potential STAT-binding sites, several IRF-1 binding sites have been found in the murine p21 promoter (Tanaka et al., 1996) suggesting that p21 could be also a critical target gene for IRF-1-mediated cell growth regulation and tumor suppression.
In the present study we analysed the role of IRF-1 and IRF-2 transcription factors in the regulation of expression of 2-5A synthetase and p21 (WAF/CP1). Our results reveal that both 2-5A synthetase and p21 genes are transactivated by IRF-1. This positive transactivation is counterbalanced by concomitant expression of IRF-2 and this inhibition is speci®c since it is abolished by antisense IRF-2. Moreover, direct binding of IRFs to the IRF-E binding site, within the human p21 gene promoter demonstrates a direct role of these transcription factors in the p21 regulation. We also show that IFN-g is able to induce expression of both IRF-1 and IRF-2 with dierent kinetics; induced IRF-1 binds to the IRF-2 promoter and stimulates IRF-2 transcription, resulting in an autoinhibitory regulation of IRF-1 activated genes.
Results
Eect of IRF-1 and IRF-2 on the in vivo activity of the 2-5A synthetase gene promoter It has been suggested that a correct balance between IRF-1 and IRF-2 factors can contribute to the control of cell growth. The expression of the 2-5A synthetase gene oscillates during the cell cycle (Jacobsen et al., 1983; Wells and Mallucci, 1985) and is regulated by IRF-1 (Reis et al., 1994) . To examine the eect of IRF-1 and IRF-2 on the regulation of the 2-5A synthetase gene promoter, the induction of 2-5A synthetase was examined in the 3Cl8 Friend leukemia cell clone which is totally resistant to type I and sensitive to type II IFN (Coccia et al., , 1995 . In this clone the induction of 2-5A synthetase by IFN-g seems essentially mediated by IRF-1. 3Cl8 cells were transiently transfected with the DCAT-E construct, in which the CAT expression was driven by the ISRE/IRF-E of the 2-5A synthetase gene and cotransfected with constructs expressing IRF-1 and IRF-2 Nguyen et al., 1995) . Where indicated cells were treated with 100 U/ml of IFN-g for 24 h (Figure 1a ). When the CAT bearing construct was cotransfected with the IRF-1-encoding plasmid a signi®cant increase in CAT activity was detected (Figure 1, lane 3) . This eect was comparable to that obtained when cells were treated with IFN-g ( Figure 1 , lane 2) demonstrating that in these cells the eect of IFN-g is mediated by IRF-1. The transactivating eect of IRF-1 expression was abolished when the IRF-2 expressing vector was cotransfected (Figure 1 , lane 5). A comparable inhibition was obtained after transfection of a truncated form of IRF-2, DIRF-2 which lacks the C-terminal end but retains the DNA binding domain (data not shown). Thus, IRF-2 exerts its inhibitory eect on IRF-1-induced transactivation of 2-5A synthetase through the DNA binding domain. The speci®city of the IRF-2 inhibitory eect on 2-5A synthetase promoter transactivation by IRF-1 was further assessed by cotransfecting 3Cl8 cells with a construct expressing antisense IRF-2 indicated as FRI-2. The activity of the FRI-2 construct was determined by its ability, after transient transfection, to inhibit the IRF-2 protein accumulation after IFN-g stimulation (Figure 1b Functional analysis of IRF-1 and IRF-2 expression on the regulation of the p21 (WAF/CP1) gene promoter Three potential IRF-Es binding sites near the MyoD binding sites were found in the mouse p21 promoter (Tanaka et al., 1996) . Similarly, by a computer assisted search we identi®ed several potential IRF-Es binding sites within the human p21 promoter depicted at the top of Figure 2 . To determine if, as demonstrated for 2-5A synthetase gene, the balance between IRF-1 and IRF-2 regulates also p21 gene, L 929 cells were transiently transfected with a construct in which the CAT expression was driven by the p21 gene promoter together with expression vectors for IRF-1 and/or IRF-2, respectively. A basal level of expression was present in control cells; when the CAT bearing construct was cotransfected with the IRF-1-encoding plasmid, a signi®cant increase in CAT activity was detected ( Figure 2) . Moreover, the transactivating eect of IRF-1 was greatly reduced when IRF-2 was coexpressed, indicating that IRF-1 participates in the induction of the p21 promoter and IRF-2 counteracts this stimulation. The same results were obtained when the DNA binding truncated form of IRF-2 was cotransfected (data not shown). No signi®cant differences in CAT gene expression were observed between control cells and IRF-2-transfected cells. Similar results were obtained in 3Cl8 cells even if a less pronounced transactivating eect of IRF-1 was observed (data not shown).
In order to determine which one of the ®ve putative IRF-Es binding sites indicated in the upper panel of Figure 2 is directly bound by the IRFs, gel shift assays were performed. Equal amounts of in vitro translated IRF-1 and IRF-2 were incubated with radiolabeled DNA corresponding to p21 promoter fragments containing potential IRF-Es binding sites. Of the sequences tested, only the region spanning from nt-1222 to nt-1190 formed distinct protein-DNA complexes (Figure 3 ). The speci®city of the formed complexes was assessed in experiments using speci®c anti-IRF-1 and anti IRF-2 antibodies, respectively. These results suggest that the regulation of the expression of the human p21 promoter shown in Figure 2 may be due to a direct binding of IRF-1 counterbalanced by the IRF-2 binding. In the left side of Figure 3 , a control experiment using an oligonucleotide corresponding to the four tandem IRF binding sites (C13) is shown. Interestingly, the dierent anities of IRF-1 and IRF-2 for this sequence, reported by Harada et al., 1989 and also evident in the ®gure (i.e., the anity of IRF-2 is ®vefold higher than that of IRF-1), is not reproduced for the sequence present in the p21 promoter.
Inhibitory feedback mechanism of IRF-1 through the induction of IRF-2 Since IFN-g is able to induce both IRF-1 and IRF-2 with dierent kinetics (see following results in Figure 5 ) and a potential IRF site has been described within the IRF-2 promoter (Harada et al., 1994b) we sought to examine if IRF-1 produced in IFN-g treated cells was able to bind to its consensus binding site in the IRF-2 promoter. Cell extracts from 3Cl8 cells at dierent times of IFN-g treatment were incubated with doublestranded radiolabeled oligonucleotide corresponding to the IRF-1 consensus binding site in the IRF-2 promoter and the complexes formed were analysed by EMSA. As shown in Figure 4 (upper part of Figure  4a ), a major complex appeared at 6 h after IFN-g treatment. The protein composition of the complex was determined by EMSA experiments performed in the presence speci®c anti-IRF-1 and anti-IRF-2 antibodies. As shown in the lower part of Figure 4a , when cell extracts from IFN-g treated cells were preincubated with anti-IRF-1 antibodies before EMSA, the formation of the IFN-g induced complex was abolished. Conversely, when the anti-IRF2 antibodies were used, the induction of the complex was still clearly detected, thus demonstrating that IRF-1 is able to bind to the IRF-2 promoter.
To test if IRF-1 regulates IRF-2 promoter in vivo, the AvaI ± TaqI (-414 to +20) IRF-2 promoter region linked to CAT was transiently transfected into 3Cl8 cells, together with expression plasmids for IRF-1 and IRF-2. The IRF-2 promoter was activated by IRF-1 Figure 3 IRFs bind to the p21 promoter. EMSA analysis was performed by incubating equal amounts of in vitro translated IRF-1 and IRF-2 with radiolabeled oligomer corresponding to putative IRF-Es binding site in the p21 promoter (p21-1200) and to the four tandem IRF binding site (C13). RRL, rabbit reticulocyte lysate, in which empty vector without an IRF-coding sequence was used as control in the translation reaction. EMSA analysis was carried out with antibodies speci®c for IRF-1 and IRF-2; pre-incubation with antibody eliminated DNA binding. Binding complexes were resolved by 4% non denaturing polyacrylamide gel electrophoresis and visualized by autoradiography Figure 4 IFN-g-induced IRF-1, binds to the IRF-2 promoter and stimulates its activity. (a) Upper panel: Total extracts from 3Cl8 cells treated for the indicated times with IFN-g were subjected to EMSA analysis using a 32 P-labeled oligomer containing the IRF motif in the human IRF-2 promoter (as indicated). (a) Lower panel: EMSA analysis was performed using polyclonal antibodies directed against IRF-1 and IRF-2 respectively, preincubated with cell extracts before their addition to the EMSA reaction; these antibodies abolished DNA binding activity. (b) CAT activity. Cells were transfected with 5 mg of the IRF-2 CAT reporter gene and 5 mg of the eector genes CMV-IRF-1 and CMV-IRF-2 respectively. Where indicated, cells were treated for 24 h with 100 U/ml IFN-g. Proteins were extracted and CAT enzymatic activity was analysed as indicated in the Materials and methods. The IRF binding site within the IRF-2 promoter is shown at the top of the ®gure expression vector to the same extent as with IFN-g treatment; activation was abolished by coexpression of IRF-2 (Figure 4b ). On the other hand, the IRF-2 alone had no eect on the IRF-2 promoter-driven CAT expression. Thus IRF-1 induces the expression of its own repressor IRF-2 through binding to the IRF-2 promoter.
Kinetics of IRFs and p21 genes induction after IFN-g treatment
To test whether the autoinhibitory feedback mechanism of IRF-1 correlated with stimulated gene induction by IFN-g, kinetic studies were performed. 3Cl8 cells were treated with 100 U/ml of IFN-g and, at the indicated times, total RNA was extracted and the IRF-1, IRF-2 and p21 mRNA expression evaluated by Northern blot (Figure 5a ) and RNase protection (Figure 5b ), respectively. IRF-1 mRNA expression appeared after 30 min and was maximal between 6 and 9 h after IFN-g treatment, whereas IRF-2 mRNA levels began to increase at 6 h and peaked between 12 and 24 h. Thus IRF-2 gene induction occurs only after induction of IRF-1 and this accounts for the involvement of IRF-1 in IRF-2 gene induction. Moreover, when the p21 mRNA accumulation was examined a strict correlation between IRF-1 induction and p21 stimulation as well as between IRF-2 expression and p21 repression was observed.
Discussion
In this study we report the eect of IRF-1 expression on the regulation of its repressor IRF-2 and the eect of the balance between these transcription factors on the expression of the 2-5A synthetase and p21 genes as potential mediators of the growth-regulatory eects induced by IFNs. Major progress has been made in understanding the ISGs regulation, although the mechanisms by which IFNs elicit antiproliferative eects have yet to be fully elucidated. The ability of IFNs to inhibit cell proliferation may be due, at least in part, to a transient induction of IRF-1 (Harada et al., 1989; Taniguchi et al., 1995) . This subtle level of regulation is also aected by alterations in the IRF-1 : IRF-2 ratio during the cell cycle. In accord with previous observations demonstrating that an IRFbinding site is present in the IRF-2 promoter and that expression of IRF-2 gene is aected by IRF-1 expression (Harada et al., 1994b) , we showed that IRF-1 induced by IFN-g is able to bind to the IRF binding site present in the IRF-2 promoter and stimulate its transcription in both erythroid (Figure 4 ) and ®broblastic cells (not shown). Kinetic studies on the IRF-1 and IRF-2 mRNA accumulation after IFN-g treatment ( Figure 5 ) further support the observation that induction of IRF-2 by IFNs or virus infection is mediated by IRF-1. The induction of IRF-2 by IRF-1, and the resulting changes in the IRF-1 : IRF-2 ratio may be regarded as a mechanism of regulation potentially relevant during the cell cycle. IRF family proteins have, in fact, growth controlling properties even in the absence of IFNs and IRF-1 binding sites are found in the promoters of many genes involved in growth control and/or oncogenesis such as IL-4, IL-5, IL-7 receptor, cyclin D1, ICAM1, p53, E-cadherin, interleukin-1 converting enzyme (ICE) . In Figure 6 some of these genes are indicated and their possible regulation by IRFs is schematized.
Several studies have demonstrated the role of IRF-1 and IRF-2 factors in the regulation of IFN type I genes (Matsuyama et al., 1993; Kamijo et al., 1994; Kimura et al., 1994) ; less clear is the direct role of IRFs in the regulation of cell growth. We analysed in particular the regulation of two genes potential target of the IFN-g induced growth inhibition mediated by IRFs: the 2-5A synthetase directly involved in the IFNmediated growth inhibition and the cell-cycle inhibitor p21 (WAF/CP1).
Both 2-5A synthetase and p21 transcription are stimulated by ectopic expression of IRF-1 in the Moreover, the inhibitory eect of IRF-2 is speci®c since it is abolished by the coexpression of an antisense RNA for IRF-2 (Figure 1 ). These results are in accord with data indicating that ectopically expressed IRF-1 and IRF-2 exert growth regulatory activity in NIH3T3 even in the absence of IFNs : IRF-1 strongly inhibiting cell proliferation, and IRF-2 inducing oncogenic transformation (Kirchho et al., 1993; Yamamoto et al., 1994; Nguyen et al., 1995) . Although we cannot formally rule out the possibility that double stranded RNA generated as a consequence of antisense expression may stimulate IFN release, it should be noted that these cells are resistant to type 1 IFN.
A novel ®nding of the present paper is the identi®cation of p21 as a potential target gene regulated by the balance between IRF-1 and IRF-2 levels. In addition to the p53-dependent induction of p21 after DNA damage (El-Deiry et al., 1994 , other sites in the p21 promoter such as the MyoD binding site and three IFN-activated GAF binding sites are involved in p21 regulation and are activated in a p53-independent manner also in response to EGF and IFN-g (Halevy et al., 1995; Parker et al., 1995; Chin et al., 1996) . In addition to the putative IRF-Es binding sites described in the murine p21 promoter (Tanaka et al., 1996) , several putative IRF-Es binding sites have been recognized in the human p21 promoter ( Figure  2a ). Moreover, we were able to demonstrate a direct binding of both IRFs to a site of the human p21 promoter (Figure 3 ). This result accounts for a direct action of IRFs and is in accord with results obtained during DNA damage (Tanaka et al., 1996) , when it appears that IRF-1 does not act through p53 in activating the p21 promoter. These results are particularly interesting in view of the oncogenic activity of IRF-2. Although IRF-2 exerts its transforming activities in part by engaging the IRF-E recognition sites and occluding the binding of IRF-1 or other regulatory proteins, the target genes of this mode of regulation are not well de®ned. p21 (WAF/CP1) may thus be considered a good candidate for this type of regulation. According to this hypothesis, p21 activation results in cell cycle arrest when IRF-1 expression is high and the oncogenic activity associated with IRF-2 may be exerted by disruption of the growth-arresting signals due to IRF-1-induced transactivation of p21. The induction kinetics of these genes, shown in Figure  5 , support a temporal induction and suppression of p21 gene expression after IFN-g stimulation of IRFs.
It has been reported that lack of IRF-1 had no eect on the IFN-induced expression levels of both IFN type 1 and some IFN-inducible genes. For 2-5A synthetase in particular, only the basal levels were decreased in IRF-7/7 cells (Runer et al., 1993) . On the other hand, for p21 Tanaka et al. showed that in IRF-1 7/7 cells no p21 mRNA was induced by irradiation (Tanaka et al., 1996) . This relatively subtle eect of IRFs on the transcription of certain genes likely re¯ects the redundant action of other transcriptional regulators such as ISGF3 whose DNA sequence recognition overlaps that of IRF (Nguyen et al., 1997b) .
In conclusion our results provide evidence that two genes involved in cell growth regulation, 2-5A synthetase and p21, are tightly regulated by the balance between IRF-1 and IRF-2 factors. Moreover the ability of IRF-1 to activate the IRF-2 gene accounts for an autoinhibitory feed-back regulation of IRF-1 activated genes which may be important for cell growth regulation.
Materials and methods

Cells cultures and IFNs
3Cl8 FLC clone (Coccia et al., 1988) was grown in RPMI 1640 supplemented with 5% fetal calf serum (FCS), penicillin (100 IU/ml) and streptomycin (100 mg/ml). L 929 cells were grown in Dulbecco supplemented with 10% FCS Figure 6 Schematic model of IRF target gene regulation and antibiotics. Cell mortality was evaluated by the trypan blue dye exclusion method and never exceeded 2%. Recombinant IFN-g (10 7 U/mg of protein) produced by Genentech and kindly provided by Boehringer Ingelheim was used at 100 U/ml. Amounts of IFNs are given in laboratory units i.e. the amounts of IFN reducing the plaque titer of vesicular stomatitis virus by 50%. This unit equals four reference units of the National Institutes of Health standard G-002-904-511.
Total RNA extraction and analysis FLCs (10 8 ) were treated as indicated and subsequently washed twice with phosphate-buered saline (PBS). Total RNA was isolated by the guanidinium-cesium chloride method (Glisin et al., 1974) . For Northern blot analysis total RNA (20 mg) was run on denaturing 1.2% agarose gels containing 0.4 M formaldehyde, transferred onto nitrocellulose ®lters, and hybridized to 32 P-labeled (1.5610 6 c.p.m./ml) IRF-1, IRF-2, and GAPDH cDNA probes (Harada et al., 1989) . cDNA probes were labeled by random priming to a speci®c activity of 0.5610 9 c.p.m./ mg. The hybridization conditions were 50 mM sodium phosphate (pH 7.0), 50% formamide, 56SSC, 46Den-hardt's solution, 0.1% sodium dodecyl sulfate (SDS), and 200 mg of single-stranded DNA per ml at 428C for 20 h (16Denhardt's solution is 0.02% each bovine serum albumin, Ficoll and polyvinylpyrrolidone). The ®lters were washed twice in 16SSC-0.1% SDS for 30 min at room temperature and twice in 0.16SSC-0.1% SDS for 30 min at 428C and exposed to X-ray ®lm. RNase protection was performed on 5 mg of total RNA hybridized for 18 h to the RNA probes (3610 5 c.p.m.) at 558C in 25 ml of 80% formamide-0.4 M NaCl-40 mM PIPES; pH 6.8-1 mM EDTA. Subsequently, samples were incubated with RNase A (40 mg/ml) and RNase T1 (1 mg/ ml) for 1 h at 338C and then subjected to Proteinase K digestion, phenol-chloroform extraction, and ethanol precipitation. Gel electrophoresis was performed on standard 8% polyacrylamide 8 M urea sequencing gel. To generate the 32 P-labeled 120 bp long antisense p21 RNA probe, the plasmid (pCMW 35, a generous gift of Dr Vogelstein) was linearized with SmaI and transcribed by T7 polymerase. The 282 bp long 18S riboprobe was used as an internal standard to establish the relative amount of RNA loaded. The probe was synthesized by in vitro transcription from linear template using SP6 polymerase.
Preparation of cell extract
Cells (2610 7 ) were washed twice in cold PBS and then collected by centrifugation. The pellet was resuspended in 200 ml of 20 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, pH 7.9], 50 mM NaCl, 10 mM EDTA, 2 mM EGTA, 0.5% NP40, 10 mM sodium molybdate, 10 mM sodium orthovanadate, 100 mM NaF, 0.5 mM PMSF, 10 mg/ml leupeptine and 0.5 mM DTT. The suspension was centrifuged at 10 000 r.p.m. for 10 min in an Eppendorf centrifuge and the supernatants were stored at 7808C.
Immunoblot assay
Western blot analysis was carried out as previously described . Brie¯y, 30 mg of total proteins from the postmitochondrial supernatant fraction were electrophoresed on 10% SDS-polyacrylamide gel and transferred onto nitrocellulose paper. The proteins were then detected by using polyclonal antibodies anti IRF-2 . Enhanced chemiluminescence system (Amersham) were used to detect immunecomplexes.
In vitro translation
Recombinant IRF-1 and IRF-2 were prepared by in vitro translation in a reticulocyte lysate system (Promega TNT system) with T7 polymerase and plasmids in which the coding region for IRF-1, IRF-2 was downstream of a T7 promoter.
DNA electrophoretic mobility shift assay (EMSA)
Synthetic double-stranded oligonucleotide prepared on an Applied Biosystems DNA synthesizer were end-labeled with g-32 P-ATP by T4 polynucleotide kinase. The labeled oligonucleotide probe (10 000 c.p.m.) was mixed with 5 mg of poly(dI)-poly(dC) (Pharmacia) and incubated for 30 min at 208C in a ®nal volume of 20 ml containing 20 mg of cell extract or equal amounts of recombinant IRFs, 60 mM NaCl, 20 mM Tris-HCl (pH 7.5), 0.2 mM EDTA, 5% (vol/vol) glycerol, 5 mM DTT. For antibody treatments, 1 ml of control or immune rabbit serum (anti-IRF-1 or anti-IRF-2) was added to 10 mg of cell extract to the reaction mixture. Analysis of DNA-protein complexes was carried out on 6% polyacrylamide gels with 0.56TBE (16TBE is 50 mM Trisborate [pH 8.2], 1 mM EDTA) as previously described (Coccia et al., 1995) .
The oligonucleotide probes used were: ±human IRF-2 promoter 5'-GAAGCGAAAATGAAATTGACTTTT-3' ±C13 (AACTGA) 4 ±human p21 promoter (-1222-1190) TTTAAAAGCAAAACTGCAAATGTTTCAGGCACA
Transfection experiments
Transfection experiments and CAT enzyme assay were performed as already described (Coccia et al., 1995) . L 929 cells (2610 7 ) were grown in 90-mm dishes for 18 h. Culture medium was then replaced with 10 ml of fresh medium 4 h before the addition of 20 mg of calcium phosphateprecipitated DNA. After 10 to 12 h, the transfection medium was replaced by fresh medium and cells were treated as described. FLC cells were transfected by electroporation: cells were harvested in the exponential growth phase, washed twice with cold PBS and resuspended at 10610 6 cells in 50 ml of cold PBS containing 10 mg of DNA. The cell suspension was allowed to sit on ice for 10 min with occasional mixing. The cell DNA suspension was then introduced into the electroporation chamber (4 mm space). A Bio-Rad gene pulser transfection apparatus was used with the following parameters: ®eld strength 0.875 KV/cm; capacitance 25 mgF; time constant *10 m s. For transfection experiments the construct pGEM D CAT-E, CMV-IRF-1, CMV-IRF-2, IRF-2 CAT, FRI-2 and p21 CAT were used. pGEM DCAT-E construct contains the 340 bp fragment spanning the NsiI site at 7264 to the SphI site at +82 of the 2-5A synthetase gene, and was obtained by a NsiI restriction of the pGEM CAT-E plasmid described in Benech et al., 1987 ; CMV-IRF-1 and CMV-IRF-2 expression vectors containing respectively IRF-1 and IRF-2 cDNA have been previously described ; IRF-2 CAT contains a bacterial CAT gene linked to AvaI ± TaqI (7414 to +20) IRF-2 promoter region (Harada et al., 1994b) ; FRI-2 contains the 360 bp AccI ± XhoI fragment (+360 to +1) of the IRF-2 gene cloned in the antisense orientation into the BstXI sites of RcCMV eukaryotic expression vector; p21 CAT contains the 2.1 Kb fragment of the human wild type p21/WAF1 gene promoter (a generous gift of Dr Vogelstein). The pSV2 CAT plasmid (not shown) was used as a control for transfection eciency and for the speci®city of IFN-g treatment (Coccia et al., 1995) .
CAT enzyme assay
Determination of total cytoplasmic CAT activity was performed according to Gorman et al. (1982) . Brie¯y, 70 mg of cell extract was incubated with 0.1 mCi of [ 14 C]chloramphenicol, 0.25 M Tris-HCl (pH 7.8) (to a ®nal volume of 150 ml) and 20 ml of 4 mM acetyl coenzyme A for 2 h. Then an additional incubation of 2 h was carried out with 20 ml of 4 mM acetyl coenzyme A. The percentage conversion [product c.p.m.6 100/(substrate c.p.m.+ product c.p.m.)] was calculated and the results from three separate experiments were expressed as the relative percentage of the conversion rate of control cells after electronic autoradiography in an Instant Imager Instrument (Camberra Packard).
